FDA warned Dominant Nutrition that LipogenX is adulterated and website claims make three products unapproved drugs.
What happened
FDA reviewed Dominant Nutrition's website in September 2021 and found it took orders for ADIPROPEN ULTRA, SUPERJOINTS, OPTIMUM-CLA, and LipogenX. FDA found LipogenX declares Hordenine as a dietary ingredient, a new dietary ingredient not shown to be marketed before October 15, 1994, without the required notification. FDA also found website claims for ADIPROPEN ULTRA, SUPERJOINTS, and OPTIMUM-CLA that intend them to treat disease, making them unapproved new drugs, and that OPTIMUM-CLA is misbranded.
What FDA found
LipogenX is adulterated because it contains Hordenine, a new dietary ingredient not marketed in the U.S. before October 15, 1994, and FDA has no information that the required premarket safety notification was submitted.
FD&C Act sections 402(f)(1)(B) and 413(a) [21 U.S.C. §§ 342(f)(1)(B) and 350b(a)]; 21 CFR 190.6FDA knows of no evidence establishing that Hordenine is safe under LipogenX's labeled conditions, so the supplement is adulterated for inadequate safety assurance.
FD&C Act sections 402(f)(1)(B) and 413(a) [21 U.S.C. §§ 342(f)(1)(B) and 350b(a)]ADIPROPEN ULTRA is an unapproved new drug because FDA cites website claims that it is 'Viagra for the Brain' and more effective than Clenbuterol as evidence it is intended for drug use.
FD&C Act sections 201(g)(1)(B), 201(p), 301(d), and 505(a) [21 U.S.C. §§ 321(g)(1)(B), 321(p), 331(d), and 355(a)]SUPERJOINTS is an unapproved new drug because website claims that it relieves joint pain and heals joint damage, fractures, tendons, and ligaments show it is intended for drug use.
FD&C Act sections 201(g)(1)(B), 201(p), 301(d), and 505(a) [21 U.S.C. §§ 321(g)(1)(B), 321(p), 331(d), and 355(a)]OPTIMUM-CLA is an unapproved new drug because website claims call it an anti-carcinogen and cancer fighter, and it is misbranded because it lacks adequate directions for use for a disease that requires a licensed practitioner.
FD&C Act sections 201(g)(1)(B), 201(p), 301(d), 505(a), 502(f)(1), and 301(a) [21 U.S.C. §§ 321(g)(1)(B), 321(p), 331(d), 355(a), 352(f)(1), and 331(a)]
What FDA wants
Within fifteen working days of receipt, notify FDA in writing of the specific steps taken to correct the violations, explain steps to prevent recurrence, and provide related documentation; if the products are not in violation, include reasoning and supporting information. If corrective action cannot be completed in that time, state the reason for delay and when it will be completed.
Who should pay attention
- dietary supplement brands using novel ingredients
- online supplement retailers
- label and website reviewers for supplement firms
This is a summary. Read the original letter on fda.gov.